Ionis Pharmaceuticals (IONS)

 

Ionis Pharmaceuticals develops and commercializes drugs used for treating various health conditions that include viral, inflammatory, metabolic, cardiovascular and dermatologic diseases, and cancer. The company is a leader in the discovery and development of antisense drug, exploiting their own novel and highly efficient drug discovery platform to generate a pipeline drugs that are first in class.

IONS’s antisense technology provides a direct route from genomics to drugs. The company discovers and conducts early development of new drugs and out-licenses their drugs to their partner companies. IONS maximizes their discovered drugs’ value by entrusting them to leading pharmaceutical companies with expertise in late-stage development, marketing, and commercialization.

Such companies include GlaxoSmithKline, Biogen Idec, Roche, AstraZeneca, and Genzyme, a Sanofi company. For instance, IONS’s partner, Genzyme, is currently commercializing KYNAMRO, IONS’s lead product, in the U.S. for homozygous familial hypercholesterolemia (HoFH) patients.

Ionis Pharmaceuticals also works with smaller companies that have the potential to exploit IONS’s technologies and drugs in areas outside of the company’s core focus. This unique business strategy allows IONS to keep their organization small and focused.  As an innovator in the discovery and development of RNA-targeted drugs, IONS has designed and implemented a patent strategy that has provided the company with strong protection for their drugs and many aspects of the discovery, development, and manufacturing of their antisense drugs.

Ionis Pharmaceuticals is traded in the OTC markets under the stock symbol IONS.  With the company’s prolific and highly-efficient drug discovery platform, they can expand their pipeline and their partners’ pipelines with antisense drugs. The company’s strategy is to discover unique, high-quality antisense drugs and then develop the drugs to key clinical value inflection points. The company’s strong financial position has resulted from their successful business strategy execution, as well as their capabilities for inventive and focused research and development.


Yahoo! Finance: ISIS News

Latest Financial News for ISIS